STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

Rhea-AI Summary
Bristol Myers Squibb (BMY) successfully completes the acquisition of Karuna Therapeutics, adding KarXT to its neuroscience portfolio. KarXT, an antipsychotic, has a novel mechanism of action with potential for multiple indications. The acquisition is expected to be dilutive to BMY's non-GAAP diluted earnings per share by approximately $0.30 in 2024 due to financing costs. The transaction includes a one-time, non-deductible Acquired In-Process Research and Development charge of approximately $12 billion. BMY plans to offset operational expenses through disciplined resource allocation and cost efficiencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
acquisition
-
News

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio announced positive FDA committee vote for Abecma in multiple myeloma treatment. Abecma's favorable benefit/risk profile was recognized based on KarMMa-3 study results. FDA review ongoing with no set action date yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
News

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Rhea-AI Summary
Bristol Myers Squibb's Breyanzi, a CD19-directed CAR T cell therapy, receives FDA accelerated approval for treating adult patients with relapsed or refractory CLL or SLL. The therapy offers a one-time infusion with 20% of patients achieving a complete response in a pivotal trial. Breyanzi is now FDA approved for large B-cell lymphoma and CLL or SLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
fda approval
News

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

Rhea-AI Summary
Bristol Myers Squibb (BMY) will release its first-quarter 2024 financial results on April 25, 2024. Investors and the public can join the conference call to hear executives discuss the results. The call will be available via webcast or phone, with materials provided beforehand. A replay will also be accessible for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
conferences earnings
-
News

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Rhea-AI Summary
Bristol Myers Squibb's Opdivo, in combination with cisplatin and gemcitabine, receives FDA approval for first-line treatment of urothelial carcinoma, showing significant improvements in overall survival and progression-free survival compared to standard treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
fda approval
-
News

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Bristol Myers Squibb (BMY) to participate in two investor conferences in March 2024. Samit Hirawat, M.D., to speak at Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
News

Bristol Myers Squibb Announces Dividend

Rhea-AI Summary
Bristol Myers Squibb (BMY) declares quarterly dividends for common and preferred stockholders, with $0.60 per share for common stock and $0.50 per share for convertible preferred stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
dividends
-
News

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Rhea-AI Summary
Bristol Myers Squibb announces positive results from the Phase 3 DAYBREAK trial, showcasing Zeposia's long-term efficacy and safety in patients with relapsing forms of multiple sclerosis. The study reveals a low annualized relapse rate, absence of confirmed disability progression, and consistent safety profile over nearly 10 years. These findings reinforce Zeposia's role as a significant treatment option for MS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
News

Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors

Rhea-AI Summary
Tapestry, Inc. (TPR) appoints Kevin Hourican and David Elkins to its Board of Directors, bringing significant strategic and financial expertise to the company. Hourican, President and CEO of Sysco Corporation, and Elkins, EVP and CFO of Bristol Myers Squibb, join as independent directors, enhancing Tapestry's global growth and transformation initiatives. The additions aim to drive innovation, shareholder returns, and sustainable growth for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
management
News

Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Bristol Myers Squibb (BMY) to participate in the TD Cowen 44th Annual Health Care Conference with Roland Chen, M.D., senior vice president. The event will take place on March 4, 2024, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
conferences

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.58 as of December 23, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 115.5B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#108 Ranked by Market Cap
#715 Ranked by Dividends

BMY Stock Data

115.55B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON